Opus Genetics, Stock Current Liabilities
| IRD Stock | 1.05 0.04 3.67% |
Opus Genetics, fundamentals help investors to digest information that contributes to Opus Genetics,'s financial success or failures. It also enables traders to predict the movement of Opus Stock. The fundamental analysis module provides a way to measure Opus Genetics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Opus Genetics, stock.
As of November 28, 2024, Total Current Liabilities is expected to decline to about 3.8 M. Opus | Current Liabilities |
Opus Genetics, Company Current Liabilities Analysis
Opus Genetics,'s Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Opus Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Opus Genetics, is extremely important. It helps to project a fair market value of Opus Stock properly, considering its historical fundamentals such as Current Liabilities. Since Opus Genetics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Opus Genetics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Opus Genetics,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Opus Current Liabilities Historical Pattern
Today, most investors in Opus Genetics, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Opus Genetics,'s growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Opus Genetics, current liabilities as a starting point in their analysis.
Opus Genetics, Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Opus Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Opus Genetics, has a Current Liabilities of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Opus Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Opus Genetics,'s direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Opus Genetics, could also be used in its relative valuation, which is a method of valuing Opus Genetics, by comparing valuation metrics of similar companies.Opus Genetics, is currently under evaluation in current liabilities category among its peers.
Opus Fundamentals
| Revenue | 19.05 M | ||||
| Net Income | (9.99 M) | ||||
| Total Debt | 4.04 M | ||||
| Cash Flow From Operations | (1.11 M) | ||||
| Number Of Employees | 14 | ||||
| Total Asset | 53.95 M | ||||
| Retained Earnings | (81.47 M) | ||||
| Working Capital | 49.91 M | ||||
| Net Asset | 53.95 M |
About Opus Genetics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Opus Genetics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Opus Genetics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Opus Genetics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Opus Genetics, is a strong investment it is important to analyze Opus Genetics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Opus Genetics,'s future performance. For an informed investment choice regarding Opus Stock, refer to the following important reports:Check out Opus Genetics, Piotroski F Score and Opus Genetics, Altman Z Score analysis. For information on how to trade Opus Stock refer to our How to Trade Opus Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Opus Genetics,. If investors know Opus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Opus Genetics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Opus Genetics, is measured differently than its book value, which is the value of Opus that is recorded on the company's balance sheet. Investors also form their own opinion of Opus Genetics,'s value that differs from its market value or its book value, called intrinsic value, which is Opus Genetics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Opus Genetics,'s market value can be influenced by many factors that don't directly affect Opus Genetics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Opus Genetics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Opus Genetics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Opus Genetics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.